TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2162270

Group type: EXPERIMENTAL
Intervention: High-intensity transcutaneous electrical stimulation (homolateral)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low-intensity transcutaneous electrical stimulation (ipsilateral)
Number of subjects: 29

Group type: COMPARATOR
Intervention: High-intensity transcutaneous electrical stimulation (contralateral)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-intensity transcutaneous electrical stimulation (homolateral) during homatropine blockade
Number of subjects: 29
Study: 442223

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Methotrexate + Fluorouracil (CMF) chemotherapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (patients operated on for breast cancer and in spontaneous menopause)
Number of subjects: 15
Study: 31983539

Group type: EXPERIMENTAL
Intervention: Overweight and obese children
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lean counterparts
Number of subjects: 200
Study: 29893462

Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX (400/100/100 mg) daily for 12 weeks
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Achieving SVR
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 147
Study: 28374512

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (SAL) via two different dry powder inhalers
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (SAL)
Number of subjects: 45
Study: 26402859

Group type: EXPERIMENTAL
Intervention: HIT (High-Intensity Interval Training)
Number of subjects: 90

Group type: COMPARATOR
Intervention: MICT (Moderate-Intensity Continuous Training)
Number of subjects: 90
Study: 23511248

Group type: EXPERIMENTAL
Intervention: Nitrite and nitrate concentrations in heparinized plasma
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Distribution of nitrite between plasma and erythrocytes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plasma nitrite and nitrate concentrations in rabbit model of ARDS
Number of subjects: 16
Study: 21160466

Group type: EXPERIMENTAL
Intervention: Nicotine patches combined with transcranial direct current stimulation (tDCS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nicotine patches combined with paired associative stimulation (PAS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo patches combined with transcranial direct current stimulation (tDCS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo patches combined with paired associative stimulation (PAS)
Number of subjects: 48
Study: 19625549

Group type: EXPERIMENTAL
Intervention: Surgeon-performed ultrasound
Number of subjects: 800
Study: 17785028

Group type: EXPERIMENTAL
Intervention: Nurse-led telemonitoring programme
Number of subjects: 55
Study: 15173543

Group type: EXPERIMENTAL
Intervention: COPE program (educational-behavioral intervention)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (structurally equivalent control program)
Number of subjects: 163
Study: 11493491

Group type: EXPERIMENTAL
Intervention: Lingual traction with Duval's forceps
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Jaw thrust
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined jaw thrust and lingual traction
Number of subjects: 30

Group type: COMPARATOR
Intervention: Jaw thrust and lingual traction used alone
Number of subjects: 30
Study: 9761804

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide (500 microg, 2.5 ml) with albuterol
Number of subjects: 434
Study: 7822626

Group type: EXPERIMENTAL
Intervention: Experimenter present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mother present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (normal boys)
Number of subjects: 0
Study: 31464975

Group type: EXPERIMENTAL
Intervention: Municipal rehabilitation starting 4 to 6 weeks postoperative
Number of subjects: 146

Group type: COMPARATOR
Intervention: No referral to rehabilitation (HOME group)
Number of subjects: 146
Study: 30419855

Group type: EXPERIMENTAL
Intervention: Occipital nerve field stimulation (ONS), active stimulation condition (ON)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Occipital nerve field stimulation (ONS), no stimulation condition (OFF)
Number of subjects: 7
Study: 27429036

Group type: EXPERIMENTAL
Intervention: Patient-specific virtual reality rehearsal (PsR) before EVAR
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (no PsR)
Number of subjects: 100
Study: 25010358

Group type: EXPERIMENTAL
Intervention: Mediterranean-type breakfast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Western-type breakfast
Number of subjects: 16
Study: 22652468

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF hydrogel (GC group, n=32)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Hydrogel without rhGM‐CSF (control group, n=33)
Number of subjects: 65
Study: 20171529

Group type: EXPERIMENTAL
Intervention: Multipurpose exercise program (n=123)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Active control group (n=123)
Number of subjects: 246
Study: 19380203

Group type: EXPERIMENTAL
Intervention: Topical diclofenac (TDiclo)
Number of subjects: 775

Group type: COMPARATOR
Intervention: DMSO vehicle
Number of subjects: 775

Group type: COMPARATOR
Intervention: Oral diclofenac (ODiclo)
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Topical diclofenac (TDiclo) + Oral diclofenac (ODiclo)
Number of subjects: 775
Study: 16412870

Group type: EXPERIMENTAL
Intervention: Treadmill exercise (TEX)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Dipyridamole stress
Number of subjects: 26
Study: 15286220

Group type: EXPERIMENTAL
Intervention: Isotonic amino acid (IAA) solution
Number of subjects: 44

Group type: COMPARATOR
Intervention: 0.25 normal saline (NS) solution
Number of subjects: 44
Study: 11389239

Group type: EXPERIMENTAL
Intervention: Tympanostomy-tube placement (TTP)
Number of subjects: 173
Study: 9240892

Group type: EXPERIMENTAL
Intervention: Low selenium state in patients with phenylketonuria
Number of subjects: 87
Study: 8237799

Group type: EXPERIMENTAL
Intervention: Intravenous 7E3 (0.1 mg/kg [n = 5], 0.2 mg/kg [n = 22], 0.15 mg/kg [n = 13], 0.25 mg/kg [n = 20])
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Chimeric 7E3 bolus (up to 0.25 mg/kg) with intravenous continuous infusion of 7E3 (10 micrograms/min for 6 to 24 hours)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Chimeric 7E3 bolus (up to 0.25 mg/kg) without intravenous continuous infusion of 7E3
Number of subjects: 124
Study: 3684122

Group type: EXPERIMENTAL
Intervention: Bromocriptine (50 mg intramuscular injection)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Estandron prolongatum (estradiol/testosterone ester combination, single intramuscular dose)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 54
Study: 28688001

Group type: EXPERIMENTAL
Intervention: Glecaprevir 400 mg + Pibrentasvir 120 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Glecaprevir 700 mg + Pibrentasvir 160 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Glecaprevir (100-1200 mg) + Pibrentasvir (40-200 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Glecaprevir (700 and 1200 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Glecaprevir up to 400 mg + Pibrentasvir
Number of subjects: 72
Study: 27149646

Group type: EXPERIMENTAL
Intervention: Prediagnostic aspirin use (1274 women)
Number of subjects: 2925

Group type: EXPERIMENTAL
Intervention: Prediagnostic aspirin use among lymph node-negative tumors
Number of subjects: 2925

Group type: EXPERIMENTAL
Intervention: Prediagnostic aspirin use among lymph node-positive tumors
Number of subjects: 2925
Study: 24060449

Group type: EXPERIMENTAL
Intervention: PA plus D (physical activity and dietary intervention)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: PA (physical activity intervention)
Number of subjects: 425

Group type: COMPARATOR
Intervention: C (control group receiving standard care)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (combined analysis)
Number of subjects: 425
Study: 22315329

Group type: EXPERIMENTAL
Intervention: Rocuronium-sugammadex (1 mg kg(‐1) rocuronium and 16 mg kg(‐1) sugammadex)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Succinylcholine (1 mg kg(‐1))
Number of subjects: 61
Study: 20537843

Group type: EXPERIMENTAL
Intervention: Small Changes (SC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Large Changes (LC)
Number of subjects: 52
Study: 18334283

Group type: COMPARATOR
Intervention: Conservative care
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Higher pain intensity on VAS
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Higher disability on RDQ
Number of subjects: 142
Study: 15950492

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily for 30 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12637609

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Interferon alfa plus low-dose cytarabine
Number of subjects: 1106
Study: 10700786

Group type: EXPERIMENTAL
Intervention: Oral tenoxicam (40 mg before surgery, 20 mg orally for 8 days)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (40 mg after surgery, 40 mg i.v. at 24 h after surgery)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 8739173

Group type: EXPERIMENTAL
Intervention: WHO probe tine at 0.25 N
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: WHO probe tine at 0.5 N
Number of subjects: 12

Group type: COMPARATOR
Intervention: Parallel-sided tine at 0.25 N
Number of subjects: 12

Group type: COMPARATOR
Intervention: Parallel-sided tine at 0.5 N
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tapered tine at 0.25 N
Number of subjects: 12

Group type: COMPARATOR
Intervention: Tapered tine at 0.5 N
Number of subjects: 12
Study: 1920175

Group type: EXPERIMENTAL
Intervention: Moderate exercise training (five 45 min sessions/week, brisk walking at 62 beta +/‐ 2% VO2max for 15 weeks)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Moderate exercise training
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nonexercise (NEX)
Number of subjects: 35
Study: 7082779

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) 50 mg administered concurrently with propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: INDERIDE (40/25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: INDERIDE (80/25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference formulations (separate tablets of INDERAL plus HYDRODIURIL)
Number of subjects: 0
Study: 31788697

Group type: EXPERIMENTAL
Intervention: High intrinsic iodine milk (IIM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Extrinsically added iodine in milk (EIM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Aqueous iodine solution (AIS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: All conditions (IIM, EIM, AIS)
Number of subjects: 12
Study: 28554458

Group type: EXPERIMENTAL
Intervention: Tooth-borne appliance
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Bone-borne appliance
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Hybrid appliance
Number of subjects: 47
Study: 25800247

Group type: EXPERIMENTAL
Intervention: Early support
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Late support
Number of subjects: 150
Study: 24932858

Group type: EXPERIMENTAL
Intervention: Integrated Care (IC) program
Number of subjects: 66

Group type: COMPARATOR
Intervention: Rational Rehabilitation (RR) program
Number of subjects: 66
Study: 23217219

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (15-minute session)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 87
Study: 18948412

Group type: EXPERIMENTAL
Intervention: CS-0777 (sphingosine 1-phosphate receptor-1 modulator)
Number of subjects: 0
Study: 18075468

Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 0
Study: 15561647

Group type: EXPERIMENTAL
Intervention: Gabapentin <1800 mg/d
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Gabapentin >=1800 mg/d
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study: 11379678

Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bupivacaine with 5 microg fentanyl
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bupivacaine with 15 microg fentanyl
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Bupivacaine with 25 microg fentanyl
Number of subjects: 124
Study: 9229060

Group type: EXPERIMENTAL
Intervention: Community mothers' programme (intervention group)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Community mothers' programme (traveller children)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Diet of traveller children
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Diet of traveller mothers
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Traveller and RCT intervention mothers
Number of subjects: 39

Group type: COMPARATOR
Intervention: Settled control mothers
Number of subjects: 39
Study: 8433726

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Immediate coronary angioplasty
Number of subjects: 142
Study: 3676923

Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 29322315

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intact casein
Number of subjects: 9
Study: 28318138

Group type: EXPERIMENTAL
Intervention: 6-month dual antiplatelet therapy (DAPT)
Number of subjects: 907

Group type: EXPERIMENTAL
Intervention: 12-month dual antiplatelet therapy (DAPT)
Number of subjects: 907
Study: 25678217

Group type: EXPERIMENTAL
Intervention: Ketotifen drops (1 drop every 12 hours) with placebo pills (2 pills daily)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo eye drops with ketotifen pills (2 pills daily)
Number of subjects: 140
Study: 23812961

Group type: EXPERIMENTAL
Intervention: Test formulation of atomoxetine hydrochloride capsules (40 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Reference formulation of atomoxetine hydrochloride capsules (40 mg)
Number of subjects: 22
Study: 21861888

Group type: EXPERIMENTAL
Intervention: Capecitabine plus bevacizumab (Cape-Bev) - capecitabine 1250 mg/m² bid for 14 days plus bevacizumab 7.5 mg/kg q3w
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) - capecitabine 800 mg/m² bid for 14 days, irinotecan 200 mg/m² on day 1, and bevacizumab 7.5 mg/kg q3w
Number of subjects: 0
Study: 19751325

Group type: EXPERIMENTAL
Intervention: Double cervical cerclage
Number of subjects: 51

Group type: COMPARATOR
Intervention: Traditional single cervical cerclage
Number of subjects: 51
Study: 17920092

Group type: EXPERIMENTAL
Intervention: Argemone mexicana decoction, Group A: once daily for 3 days, n=23
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Argemone mexicana decoction, Group B: twice daily for 7 days, n=40
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Argemone mexicana decoction, Group C: four times daily for the first 4 days followed by twice daily for 3 days, n=17
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall response in children aged <1 year
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall response in patients aged >5 years
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with ACR at Day 14
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Side effects observed
Number of subjects: 80
Study: 15151520

Group type: EXPERIMENTAL
Intervention: (R)-methadone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: (S)-methadone
Number of subjects: 59
Study: 11393876

Group type: EXPERIMENTAL
Intervention: Circle feedback with instructions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Circle feedback without instructions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Limb feedback with instructions
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Limb feedback without instructions
Number of subjects: 4
Study: 9821899

Group type: EXPERIMENTAL
Intervention: Concentric-Eccentric Resistance Training
Number of subjects: 16
Study: 8624291

Group type: EXPERIMENTAL
Intervention: Cisplatin (50 mg/m2, repeated courses every 28 days for 6 cycles)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 271
Study: 2665423

Group type: EXPERIMENTAL
Intervention: Cytobrush and Ayre spatula
Number of subjects: 205

Group type: COMPARATOR
Intervention: Extended-tip spatula
Number of subjects: 205
Study: 1096922

Group type: EXPERIMENTAL
Intervention: Experimental drugs (various local anaesthetic agents)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Standard local anaesthetic agent
Number of subjects: 1
Study: 30371145

Group type: EXPERIMENTAL
Intervention: Insult (verbal behaviour designed to offend and upset the performer)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distraction (verbal behaviour designed to draw attention away from the task)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (neutral verbal behaviour)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall effect of verbal antisocial behaviour
Number of subjects: 0
Study: 27435295

Group type: EXPERIMENTAL
Intervention: MTX-PG concentrations in erythrocytes
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: MTX-PG1-5 > 50.6 nM at 8 weeks
Number of subjects: 98

Group type: COMPARATOR
Intervention: MTX-PG1-5 ≤ 50.6 nM at 8 weeks
Number of subjects: 98
Study: 25554994

Group type: EXPERIMENTAL
Intervention: sertraline
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: escitalopram
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: venlafaxine extended-release
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (non-melancholic patients)
Number of subjects: 339
Study: 23185988

Group type: EXPERIMENTAL
Intervention: Early intensive care management
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Time between respiratory symptoms onset and ICU admission > 2 days
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: More than one line of chemotherapy
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Oxygen flow at admission
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Extra-respiratory symptoms
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Logistic organ dysfunction (LOD) score at admission
Number of subjects: 219
Study: 22027749

Group type: EXPERIMENTAL
Intervention: Myocet (60 mg/m intravenously on day 1 every 4 weeks)
Number of subjects: 18
Study: 19392956

Group type: EXPERIMENTAL
Intervention: Toileting assistance every 2 hours for 2 days
Number of subjects: 111

Group type: COMPARATOR
Intervention: Usual NH care
Number of subjects: 111
Study: 17597524

Group type: EXPERIMENTAL
Intervention: Electrical neurostimulation (5 minutes before plus 1 minute during the first episode)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electrical neurostimulation (5 minutes before plus 1 minute during the second episode)
Number of subjects: 60
Study: 15142030

Group type: EXPERIMENTAL
Intervention: 1.5 g carbohydrate (CHO)/kg body mass carbohydrate beverage (25% solution)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11517127

Group type: EXPERIMENTAL
Intervention: EPO therapy (100 U x kg(‐1) s.c. three times a week for 3 weeks before surgery and i.v. on the day of surgery)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (age-matched patients who underwent open heart surgery during the two preceding years)
Number of subjects: 39
Study: 9663725

Group type: EXPERIMENTAL
Intervention: Omeprazole plus azithromycin and amoxycillin (OAzA group: n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Omeprazole plus azithromycin and metronidazole (OAzM group: n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: OAzA group
Number of subjects: 100

Group type: COMPARATOR
Intervention: OAzM group
Number of subjects: 100
Study: 8114860

Group type: EXPERIMENTAL
Intervention: Acyclovir for 7 days with prednisolone
Number of subjects: 400

Group type: COMPARATOR
Intervention: Acyclovir for 7 days with placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Acyclovir for 21 days with prednisolone
Number of subjects: 400

Group type: COMPARATOR
Intervention: Acyclovir for 21 days with placebo
Number of subjects: 400
Study: 2629624

Group type: EXPERIMENTAL
Intervention: Cereal based oral rehydration solution (made of maize, millet, sorghum, or rice)
Number of subjects: 257

Group type: COMPARATOR
Intervention: World Health Organisation/United Nations Childrens Fund (WHO/Unicef) recommended oral rehydration solution
Number of subjects: 257
Study: 786421

Group type: EXPERIMENTAL
Intervention: Disulfiram implants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham operations
Number of subjects: 0
Study: 31236778

Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) with catheter (Group I, n=350 patients)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Intraarticular analgesic infusion (IAC) (Group II, n=172 patients)
Number of subjects: 511
Study: 29196485

Group type: EXPERIMENTAL
Intervention: Intervention arm (multicomponent obesity prevention programme)
Number of subjects: 1640

Group type: COMPARATOR
Intervention: Usual practice (control arm)
Number of subjects: 1640

Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 1640
Study: 25849623

Group type: EXPERIMENTAL
Intervention: FEP without cannabis misuse
Number of subjects: 81

Group type: COMPARATOR
Intervention: FEP with cannabis misuse
Number of subjects: 81
Study: 23757614

Group type: EXPERIMENTAL
Intervention: Low-dose vitamin C (250 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Medium-dose vitamin C (500 mg/day)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose vitamin C (1,000 mg/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No supplemental vitamin C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-caloric content meal
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vitamin C (all dosages)
Number of subjects: 8
Study: 16441729

Group type: EXPERIMENTAL
Intervention: Aggressive periodontitis (AP) subjects
Number of subjects: 39

Group type: COMPARATOR
Intervention: Periodontally healthy individuals (PH)
Number of subjects: 39